BeiGeneius Webinar #7

Highlights from ASH 2021: Practice-changing developments

Next-generation BTK inhibitors for relapsed/refractory B-cell malignancies: What are the options and how do they compare?

Diagnosis and prognosis in CLL/SLL

Navigating treatment options for stage I and II NSCLC

Waldenström’s macroglobulinemia and the role of BTK inhibitors